Who is eligible for clinical trial NCT02633111?

Participants must meet protocol criteria for B-cell Non-Hodgkin Lymphoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02633111 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-11-03

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas (NCT02633111)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Memorial Sloan Kettering Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can potentially replace CT scans after completion of chemotherapy in the future.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (5 items).

Location: University of Miami — Miami, Florida

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

18 years of age at time of signing informed consent
Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma
De novo diffuse large B-cell lymphoma (including all subtypes such as primary mediastinal B-cell lymphoma and T-cell rich B-cell lymphoma). According to the 2008 WHO Classification of Hematopoietic and Lymphoid Tumors. These would include double or triple-hit diffuse large B-cell lymphomas with MYC/BCL2 and/or BCL6 gene rearrangements. These cases may be classified as high grade B-cell lymphomas according to the 2017 revision of the WHO Classification of Hematopoietic and Lymphoid Tumors.
Recipient of frontline multi-agent chemotherapy (for example, RCHOP, dose adjusted-REPOCH, RCHOP/RICE, RCHOP+investigational agent, etc). Eligible patients will have recently received (≤ 4 months from end of treatment assessment), be actively receiving, or planned to receive frontline chemotherapy in near future (within 3 months of signing consent). A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.
Required pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype.
Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and MRD test specimen collection at specified time points.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients receiving 2nd or greater line of therapy.
Stage I or II disease.
Primary mediastinal B-cell lymphoma.
Transformation from antecedent or coincident indolent B-cell Non-Hodgkin lymphoma.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

University of Miami — Miami, Florida
Mayo Clinic — Rochester, Minnesota
Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Memorial Sloan Kettering Bergen — Montvale, New Jersey
Memorial Sloan Kettering Commack — Commack, New York
Memorial Sloan Kettering Cancer Center — Harrison, New York
Memorial Sloan Kettering Westchester — Harrison, New York
Memorial Sloan Kettering Cancer Center — New York, New York
Memorial Sloan Kettering Nassau — Uniondale, New York
University of Pennsylvania — Philadelphia, Pennsylvania
Md Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗